State Key Laboratory of the Fine Chemicals, Dalian University of Technology, Dalian 116023, PR China; Key Laboratory of Biotechnology and Bioresources Utilization of Ministry of Education of Life Sciences, Dalian Minzu University, Dalian 116600, PR China.
Key Laboratory of Biotechnology and Bioresources Utilization of Ministry of Education of Life Sciences, Dalian Minzu University, Dalian 116600, PR China.
Carbohydr Polym. 2021 Jan 1;251:117103. doi: 10.1016/j.carbpol.2020.117103. Epub 2020 Sep 22.
The polysaccharide-based biomaterials hyaluronic acid (HA) and chondroitin sulfate (CS) have aroused great interest for use in drug delivery systems for tumor therapy, as they have outstanding biocompatibility and great targeting ability for cluster determinant 44 (CD44). In addition, modified HA and CS can self-assemble into micelles or micellar nanoparticles (NPs) for targeted drug delivery. This review discusses the formation of HA- and CS-based NPs, and various types of CS-based NPs including CS-drug conjugates, CS-polymer NPs, CS-small molecule NPs, polyelectrolyte nanocomplexes (PECs), CS-metal NPs, and nanogels. We then focus on the applications of HA- and CS-based NPs in tumor chemotherapy, gene therapy, photothermal therapy (PTT), photodynamic therapy (PDT), sonodynamic therapy (SDT), and immunotherapy. Finally, this review is expected to provide guidelines for the development of various HA- and CS-based NPs used in multiple cancer therapies.
基于多糖的生物材料透明质酸(HA)和硫酸软骨素(CS)因其出色的生物相容性和对簇集分化抗原 44(CD44)的靶向能力而在肿瘤治疗的药物传递系统中引起了极大的兴趣。此外,经过修饰的 HA 和 CS 可以自组装成胶束或胶束纳米颗粒(NPs)以实现靶向药物传递。本综述讨论了基于 HA 和 CS 的 NPs 的形成,以及各种类型的 CS 基 NPs,包括 CS-药物偶联物、CS-聚合物 NPs、CS-小分子 NPs、聚电解质纳米复合物(PECs)、CS-金属 NPs 和纳米凝胶。然后,我们重点介绍了基于 HA 和 CS 的 NPs 在肿瘤化疗、基因治疗、光热治疗(PTT)、光动力治疗(PDT)、声动力治疗(SDT)和免疫治疗中的应用。最后,本综述有望为多种癌症治疗中使用的各种基于 HA 和 CS 的 NPs 的开发提供指导。
Carbohydr Polym. 2021-1-1
Carbohydr Polym. 2020-1-11
Int J Nanomedicine. 2018-7-10
Expert Opin Drug Deliv. 2019-8-6
Colloids Surf B Biointerfaces. 2017-7-18
Int J Nanomedicine. 2025-8-9
J Nanobiotechnology. 2025-5-20
Anticancer Agents Med Chem. 2025
Exp Hematol Oncol. 2025-1-31